Larimar Therapeutics
LRMR
80 hedge funds and large institutions have $126M invested in Larimar Therapeutics in 2016 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 32 reducing their positions, and 15 closing their positions.
514% more call options, than puts
Call options by funds: $2.67M | Put options by funds: $435K
0% more capital invested
Capital invested by funds: $126M → $126M (+$501K)
8% less funds holding
Funds holding: 87 → 80 (-7)
19% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 32
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
47% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$14.6M |
| 2 |
D.E. Shaw & Co
New York
|
+$2.21M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$1.18M |
| 4 |
VMI
VHCP Management II
New York
|
+$931K |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$488K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$8.39M |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$2.65M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.43M |
| 4 |
CC
Clearline Capital
New York
|
-$2.36M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$1.55M |
LRMR Hedge Fund Activity: Q1 2016 in Review
80 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q1 2016, worth a combined $126M — up 0.4% from $126M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of LRMR and 8 opened new positions — a net loss of 7 holders — while 32 trimmed existing stakes and 26 added.
The largest buyer was Deerfield Management, adding an estimated $14.6M. The largest seller was State Street, cutting an estimated $8.39M.
- 80 institutional investors held Larimar Therapeutics (LRMR) as of Q1 2016, down from 87 in Q4 2015.
- Funds reported $126M of Larimar Therapeutics stock for Q1 2016, up 0.4% quarter-over-quarter.
- 8 funds opened new Larimar Therapeutics positions in Q1 2016 and 15 closed out, a net change of -7 holders.
- The largest Larimar Therapeutics buyer in Q1 2016 was Deerfield Management, an estimated $14.6M added.
- The largest Larimar Therapeutics seller in Q1 2016 was State Street, an estimated $8.39M sold.
Based on aggregated 13F filings for Q1 2016.